These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors. Skouby SO, Sidelmann JJ, Nilas L, Gram J, Jespersen J. Climacteric; 2008 Aug; 11(6):489-97. PubMed ID: 18991076 [Abstract] [Full Text] [Related]
17. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Mueck AO, Genazzani AR, Samsioe G, Vukovic-Wysocki I, Seeger H. Menopause; 2007 Aug; 14(6):978-84. PubMed ID: 17595593 [Abstract] [Full Text] [Related]
18. [Hormone replacement therapy and the cardiovascular system: on the role of hemostasis]. Winkler UH. Zentralbl Gynakol; 1995 Aug; 117(10):510-5. PubMed ID: 7491833 [Abstract] [Full Text] [Related]
19. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. Rosano GM, Maffei S, Andreassi MG, Vitale C, Vassalle C, Gambacciani M, Stramba-Badiale M, Mercuro G. J Cardiovasc Med (Hagerstown); 2009 Jan; 10(1):85-92. PubMed ID: 19145119 [Abstract] [Full Text] [Related]